Healthcare Industry News:  chronic kidney disease 

Biopharmaceuticals Personnel

 News Release - March 3, 2006

Acologix Strengthens Management Team With Addition of CFO

HAYWARD, Calif., March 3 (HSMN NewsFeed) -- Acologix Inc., a privately held biopharmaceutical company, announced the appointment of John J. Buckley as Chief Financial Officer. Mr. Buckley will be responsible for financial reporting and financial operations of the Company.

"The addition of Mr. Buckley, who brings over 20 years of financial management experience primarily with high-growth life science companies, completes and strengthens our management team," said Yoshi Kumagai, President and CEO of Acologix. "His strong track record of achievement will benefit the Company tremendously as we enter the next phase of our corporate development, continue to advance of our diverse, late-stage product pipeline and expand and diversify our clinical, partnering and financing efforts."

Mr. Buckley was previously at Ernst & Young LLP, where he served as a Partner of the firm and Director of the Pacific Northwest Life Sciences Practice. During his tenure of 16 years at Ernst &Young, he advised numerous public and private companies on initial and follow-on public offerings, creative and versatile financing structures, accounting and auditing matters, SEC reporting and mergers and acquisitions. Mr. Buckley also served as CFO of The Dr. Spock Company, a parenting media and merchandising company focused on children's health and healthy parenting.

He received his BBA in Accounting from the University of Wisconsin - Whitewater and is a Certified Public Accountant.

About Acologix

Acologix, a privately held biopharmaceutical company, is developing and commercializing innovative biopharmaceuticals targeting osteo-renal diseases, including chronic kidney disease, renal osteodystrophy, bone repair and regeneration, periodontal disease, general dentistry and oral care. Acologix is partnering with Toray Industries, Inc. of Japan on the development and commercialization of AC-820 (or TRK-820) for the treatment of uremic pruritus in dialysis patients. AC-820 is being studied in a European Phase 3 pivotal clinical trial, with a United States Phase 3 trial scheduled to launch in the second half of 2006. AC-100 (Dentonin®), a novel small peptide with dental and orthopedic applications, is currently being studied in two Phase 2 clinical studies, one in dental restoration procedures and another for the repair of periodontal defects. For more information, go to www.acologix.com.

This press release contains "forward-looking" statements. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements include statements regarding product development and cannot be guaranteed. Acologix undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Acologix's business.


Source: Acologix

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.